Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook

About this update from Seer, Inc.

[{"type":"image","alt":"Seer, Inc.","displaySize":"","headline":null,"caption":"Seer, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":95,"url":"https://media.zenfs.com/en/globenewswire.com/54cda3f3cc4c5a0012780bcda6451a0b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WjE6r23jRNel_7Qf6Kuejw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/54cda3f3cc4c5a0012780bcda6451a0b","width":300,"height":95}},"lazy":false},{"type":"text","content":"REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025.","length":248,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year 2025","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insight","length":182,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong presence at the 2025 Human Proteome Organization World Congress with more than a dozen scientific presentations and sixteen posters presented that highlight the translational power of the Proteograph","length":206,"tagName":"p"}]},{"val":[{"type":"text","content":"Ended the year with approximately $240.6 million of cash, cash equivalents and investments","length":90,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":727,"olType":false},{"type":"text","content":"“2025 was a challenging year as our customers navigated ongoing budgetary pressures, including uncertainty around NIH funding in the fourth quarter," said Omid Farokhzad, Chair and CEO of Seer. "Despite this persistently challenging funding environment, we made meaningful progress across our business. Our installed base grew si...

More updates from Seer, Inc.